卫材在中国推出失眠症治疗药“达卫可”

Core Viewpoint - The article discusses the launch of Dayvigo, a drug developed by Eisai, in China for the treatment of insomnia, targeting the neuropeptide orexin associated with wakefulness [2][4]. Group 1: Product Launch and Approval - Dayvigo was officially launched in China on August 18, following its approval by the National Medical Products Administration (NMPA) in May [4]. - The drug is aimed at adult patients suffering from insomnia, a condition affecting approximately 15% of the adult population in China, translating to around 172.5 million individuals [4]. Group 2: Market Potential and Sales Forecast - Eisai anticipates that the sales of Dayvigo will increase by 8% year-on-year, reaching 58 billion yen in the fiscal year ending March 2026 [4]. - Dayvigo is positioned alongside other key products from Eisai, including the cancer drug Lenvima and the Alzheimer's treatment Leqembi [4].